Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors

Background Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies. However, the clinical relevance of CD47 expression in LNET has remained unclear. Methods We performed a retrospective study in which we analyzed tumor biopsies from 51 patients with a confirmed diagnosis of LNET that received treatment at our hospital. Then, we analyzed if there was any correlation between CD47 expression with any clinical or pathological characteristic. We also analyzed the prognostic significance of CD47, assessed as progression-free survival and overall survival. Results A total of 51 patients with LNET were enrolled in our study. The mean age at diagnosis was 57.6 (±11.6) years; 30 patients were women (59%). 27.5% of patients were positive for CD47 expression, and 72.5% of patients showed a CD47 expression of less than 1% and were considered as negatives. In patients with high-grade tumors (this time defined as Ki‐67 > 40%), the positive expression of CD47 was strongly associated with an increased PFS. Albeit, these differences did not reach statistical significance when analyzing OS. Conclusion Contrary to what happens in a wide range of hematologic and solid tumors, a higher expression of CD47 in patients with LNET is associated with a better progression-free survival, especially in patients with a Ki‐67 ≥ 40%. This “paradox” remains to be confirmed and explained by larger studies.

[1]  O. Arrieta,et al.  CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer , 2020, Journal of immunology research.

[2]  F. Hirsch,et al.  Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution , 2020, Molecular oncology.

[3]  Jianguo Xu,et al.  CD47: the next checkpoint target for cancer immunotherapy. , 2020, Critical reviews in oncology/hematology.

[4]  Caicun Zhou,et al.  Immunotherapy as a treatment for small cell lung cancer: a case report and brief review , 2020, Translational lung cancer research.

[5]  A. Ricci,et al.  Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia , 2020, Cancers.

[6]  A. Akarca,et al.  Programmed Cell Death Ligand Expression Drives Immune Tolerogenesis across the Diverse Subtypes of Neuroendocrine Tumours , 2020, Neuroendocrinology.

[7]  A. Cardona,et al.  Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer , 2020, Cancer medicine.

[8]  M. Triggiani,et al.  Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC , 2020, Frontiers in Immunology.

[9]  G. Pelosi,et al.  The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis , 2019, BMJ Open.

[10]  Chuang Chen,et al.  High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis , 2019, Oncology letters.

[11]  M. Ladanyi,et al.  Stage IV Lung Carcinoids: Spectrum and Evolution of Proliferation Rate, Focusing on Variants with Elevated Proliferation Indices , 2019, Modern Pathology.

[12]  I. Weissman,et al.  CD47 Blockade by Hu5F9‐G4 and Rituximab in Non‐Hodgkin's Lymphoma , 2018, The New England journal of medicine.

[13]  M. Dietel,et al.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal , 2018, Modern Pathology.

[14]  J. Parsons,et al.  CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer , 2017, Clinical Cancer Research.

[15]  G. Pelosi,et al.  Classification of pulmonary neuroendocrine tumors: new insights. , 2017, Translational lung cancer research.

[16]  Xianglin Yuan,et al.  Thrombospondin-1 is a multifaceted player in tumor progression. , 2017, Oncotarget.

[17]  Lin F. Yang,et al.  Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells , 2017, Front. Immunol..

[18]  Lu Gao,et al.  Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells , 2016, Cell Death and Disease.

[19]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[20]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[21]  Lu Gao,et al.  CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis , 2016, Oncotarget.

[22]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[23]  W. Travis,et al.  Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  W. Travis Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. , 2014, Thoracic surgery clinics.

[25]  W. Travis,et al.  Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  L. Martiny,et al.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest , 2012, British journal of pharmacology.

[27]  I. Weissman,et al.  Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells , 2012, Leukemia.

[28]  I. Weissman,et al.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. , 2011, Blood.

[29]  D. Roberts,et al.  Thrombospondin-1 Inhibits VEGF Receptor-2 Signaling by Disrupting Its Association with CD47* , 2010, The Journal of Biological Chemistry.

[30]  D. Roberts,et al.  Treatment of liver ischemia-reperfusion injury by limiting thrombospondin-1/CD47 signaling. , 2008, Surgery.

[31]  G. Fortin,et al.  CD47 in the immune response: role of thrombospondin and SIRP-alpha reverse signaling. , 2008, Current drug targets.

[32]  Julia Fukuyama,et al.  Thrombospondin-1 Inhibits Nitric Oxide Signaling via CD36 by Inhibiting Myristic Acid Uptake* , 2007, Journal of Biological Chemistry.

[33]  D. Ettinger Overview and state of the art in the management of lung cancer. , 2004, Oncology.

[34]  Partha Pratim Manna,et al.  CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A , 2004, Cancer Research.

[35]  N. Pedersen,et al.  Transcriptional gene expression profiling of small cell lung cancer cells. , 2003, Cancer research.

[36]  Z. Baloch,et al.  Neuroendocrine tumors of the thyroid gland. , 2001, American journal of clinical pathology.

[37]  H. Krutzsch,et al.  Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. , 2000, Cancer research.

[38]  M. Sarfati,et al.  Dendritic Cells Production and Maturation of Human CD47 Engagement Inhibits Cytokine , 2000 .